Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates

01.08.2023 - WAKIX (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023 Exited Second Quarter 2023 With ~5,600 ...

Related Keywords

United States ,Americans ,Jeffreym Dayno ,Luis Sanay ,Exchange Commission ,Million Share Repurchase Program ,Company Updates ,Drug Administration ,Company Nasdaq ,Harmony Biosciences Holdings Inc ,Paragon Biosciences ,Completed Enrollment ,Topline Data ,Fourth Quarter ,Initiate Prader Willi Syndrome ,Directors Authorized ,Share Repurchase ,Held Today ,Biosciences Holdings ,Chief Executive Officer ,Operating Expenses ,Myotonic Dystrophy ,Call Today ,Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Months Ended June ,Biosciences Investor Contact ,Harmony Biosciences Holdings ,